Sirukumab

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

669 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Sirukumab.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Sirukumab.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sirukumab.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Sirukumab.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Sirukumab.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sirukumab.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Sirukumab.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Sirukumab.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Sirukumab.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sirukumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Sirukumab.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sirukumab.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Sirukumab.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Sirukumab.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Sirukumab.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sirukumab.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Sirukumab.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Sirukumab.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Sirukumab.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sirukumab.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Sirukumab.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sirukumab.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Sirukumab.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Sirukumab.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sirukumab.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Sirukumab.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Sirukumab.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Sirukumab.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Sirukumab.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Sirukumab.
Cladribine	Sirukumab may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Sirukumab.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Sirukumab.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Sirukumab.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Sirukumab.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Sirukumab.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Sirukumab.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Sirukumab.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Sirukumab.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Sirukumab.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Sirukumab.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Sirukumab.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Sirukumab.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sirukumab.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Sirukumab.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Sirukumab.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Sirukumab.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Sirukumab.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Sirukumab.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Sirukumab.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Sirukumab.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Sirukumab.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Sirukumab.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Sirukumab.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Sirukumab.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Sirukumab.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Sirukumab.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sirukumab.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sirukumab.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Sirukumab.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sirukumab.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sirukumab.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Sirukumab.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Sirukumab.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Sirukumab.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Sirukumab.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Sirukumab.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Sirukumab.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Sirukumab.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Sirukumab.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Sirukumab.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Sirukumab.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Sirukumab.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Sirukumab.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Sirukumab.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Sirukumab.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sirukumab.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Sirukumab.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Sirukumab.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Sirukumab.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Sirukumab.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Sirukumab.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Sirukumab.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Sirukumab.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Sirukumab.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Sirukumab.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Sirukumab.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Sirukumab.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Sirukumab.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sirukumab.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Sirukumab.
Cytarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Sirukumab.
Azathioprine	The risk or severity of adverse effects can be increased when Azathioprine is combined with Sirukumab.
Doxorubicin	The risk or severity of adverse effects can be increased when Doxorubicin is combined with Sirukumab.
Hydroxyurea	The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Sirukumab.
Busulfan	The risk or severity of adverse effects can be increased when Busulfan is combined with Sirukumab.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Sirukumab.
Topotecan	The risk or severity of adverse effects can be increased when Topotecan is combined with Sirukumab.
Mercaptopurine	The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Sirukumab.
Thalidomide	The risk or severity of adverse effects can be increased when Thalidomide is combined with Sirukumab.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual